Japan’s FY2026 Drug Pricing Reform

Articles
Written By Adam Foster

Japan’s FY2026 Drug Pricing Reform

Article written by Jason King, Anoud Naeem and Amy Morgan, Windrose Consulting Group

A Decade of Structural Price Tightening

Over the past decade, Japan’s pharmaceutical pricing system has undergone several key changes in response to growing fiscal pressure and rapid population aging. The National Health Insurance (NHI) system has shifted from biennial to annual price revisions and expanded repricing triggers such as Market Expansion Repricing (MER). Collectively, these reforms have created sustained downward pressure on patented medicines and reduced long-term price predictability for innovative therapies [1] .

Industry stakeholders argue that the recent policy reforms are already influencing Japan’s position within the global pharmaceutical ecosystem. According to the Japan Pharmaceutical Manufacturers Association (JPMA), while global biopharmaceutical R&D investment doubled between 2012 and 2022, Japan’s share declined from 12% to 6% over the same period [2]. This decline has been linked to growing concerns of “drug lag” and “drug loss,” referring to delayed or foregone launches of globally available therapies in the Japanese market.

Additionally, industry associations have warned that US international reference pricing approaches, including the evolving Most Favoured Nation-type models, include Japan’s comparatively low prices in reference baskets, potentially exacerbating hesitancy surrounding the launch of novel therapeutics in Japan [3]. Within this context, Japan’s FY2026 drug pricing reform has key implications for both domestic and international stakeholders.

FY2026 Reform: Confirmed Structural Changes

The FY2026 NHI Drug Pricing System Reform, announced by the Central Social Insurance Medical Council (Chuikyo) Drug Pricing Specialist Subcommittee, aligns with recent trends of cost-containment policy [4]. NHI aggregate drug prices will be reduced by 0.86% on a healthcare expenditure basis through the most recent annual Standard Market Survey-Based Price Revision, generating approximately ¥105 billion in savings, accounting for roughly 70% of the ¥150 billion total healthcare reform savings projected for FY2026 [5].

At the same time, marketability premiums will be revised “to promote continued investment in drug development,” including incentives for simultaneous adult and paediatric development programs [6].

The reform also abolishes the spillover rule, which previously allowed price reductions to be applied to therapeutically similar drugs when a product triggered Market Expansion Repricing (MER). Under the previous framework, price cuts could extend beyond the trigger product to other medicines within the same therapeutic class, even if their own sales had not exceeded forecasts. The FY2026 drug pricing reform outline approved by the Central Social Insurance Medical Council (Chuikyo) confirms that these spillover price cuts will be abolished [1]. However, the reform framework also indicates that authorities will continue monitoring utilisation trends for similar drugs and may introduce measures if necessary. In practice, this monitoring mechanism allows policymakers to assess whether prescribing shifts toward comparable therapies following an MER-triggered adjustment and, if spending growth persists within the therapeutic class, to consider targeted policy responses in future pricing revisions. As a result, although the automatic spillover repricing mechanism is formally removed, a degree of therapeutic class-level repricing uncertainty remains.

Blockbuster repricing has been retained and strengthened. The former “huge seller repricing” mechanism under MER has been reframed to the new Special Price Adjustment for Sustainable Health System and Sales Scale (SPA-SSS). If annual sales exceed ¥300 billion and reach more than 10x the original forecast, the maximum price reduction will increase from 50% to 66.7% [6], increasing repricing risk for high-performing products.

Additionally, international repricing rules have been updated, such that only post-AMNOG negotiated prices in Germany are considered in the reference basket, rather than pre-AMNOG launch prices (under free pricing) [6]. This effectively incorporates net pricing outcomes into price calculations, rather than just the list prices referenced in France, UK, and US (ASP & NADAC), narrowing global pricing corridors.

As an upside to the FY2026 pricing reforms, SECM I (similar efficacy comparison method) pricing rules have been updated. If the comparison drug has received a correction premium, the daily drug price will be adjusted based on the comparator price minus that premium, making it easier to apply the correction premium to the new drug as well. This removes the prior restriction on reapplying comparator premiums, expanding access to premium pricing and PMP eligibility.

Unresolved Reform Elements

Alongside the confirmed policy changes above, Chuikyo working groups are reviewing comparator drug selection criteria for the comparator-based pricing method and examining the scope of cost disclosure in the cost-based pricing approach. Current discussions focus on improving transparency around manufacturer-reported cost components, such as manufacturing costs, R&D expenditure, marketing expenses, and operating margins, to ensure more consistent pricing calculations [6].

Additionally, while Japan has historically positioned itself as a regulatory leader in regenerative medicine, many argue that pricing frameworks have not evolved at the same pace. In particular, the continuing absence of novel modality-specific pricing methodologies (e.g., for stem cell / gene therapy) introduces uncertainty for sponsors planning advanced therapy launches.

Industry Reaction and Concerns

In December 2025, JPMA, EFPIA (European Federation of Pharmaceutical Industries and Associations) Japan, and PhRMA (Pharmaceutical Research and Manufacturers of America) issued a joint statement raising concerns about the direction of reform. They note that a considerable proportion of patented drugs are still likely to be ineligible for PMP and therefore subject to annual price cuts even during exclusivity [2]. Even PMP-eligible products remain exposed to other post-launch repricing mechanisms, including Market Expansion Repricing (MER) and price adjustments following cost-effectiveness analysis (CEA), meaning that price stability during the patent period is not fully guaranteed.

Additionally, industry representatives also highlight the asymmetry of Japan’s CEA system. While CEA has been used to implement post-launch price reductions for high-cost drugs, no upward price adjustments have been approved to date [2]. This creates a one-directional pricing system, where value is seen to be penalized but not subsequently rewarded.

Industry stakeholders had proposed abolishing huge-seller repricing, expanding comparator scope to better capture therapeutic value, introducing post-launch upward price adjustments based on real-world evidence, and establishing dedicated pricing frameworks for regenerative modalities. They also called for ending annual price survey-based revisions for patented products. With the exception of partial spillover rule removal, these proposals were not adopted [3].

Industry Reaction and Concerns

In December 2025, JPMA, EFPIA (European Federation of Pharmaceutical Industries and Associations) Japan, and PhRMA (Pharmaceutical Research and Manufacturers of America) issued a joint statement raising concerns about the direction of reform. They note that a considerable proportion of patented drugs are still likely to be ineligible for PMP and therefore subject to annual price cuts even during exclusivity [2]. Even PMP-eligible products remain exposed to other post-launch repricing mechanisms, including Market Expansion Repricing (MER) and price adjustments following cost-effectiveness analysis (CEA), meaning that price stability during the patent period is not fully guaranteed.

Additionally, industry representatives also highlight the asymmetry of Japan’s CEA system. While CEA has been used to implement post-launch price reductions for high-cost drugs, no upward price adjustments have been approved to date [2]. This creates a one-directional pricing system, where value is seen to be penalized but not subsequently rewarded.

Industry stakeholders had proposed abolishing huge-seller repricing, expanding comparator scope to better capture therapeutic value, introducing post-launch upward price adjustments based on real-world evidence, and establishing dedicated pricing frameworks for regenerative modalities. They also called for ending annual price survey-based revisions for patented products. With the exception of partial spillover rule removal, these proposals were not adopted [3].

Implications for Manufacturers

The FY2026 reforms reshape the economics of product launches in Japan, impacting the associated risk for manufacturers. The transformation of huge seller repricing to SPA-SSS creates heightened exposure for high-revenue therapies, incentivizing realistic forecasting to avoid repricing due to underestimated sales.

Narrowing foreign price referencing further integrates Japan into global pricing dynamics but effectively narrows the reference basket, constraining the scope for upward foreign price adjustments (FPA). Combined with tightening U.S. reference pricing and Japan’s role in MFN frameworks, this increases the risk of downward price convergence and may discourage launches to avoid setting low global benchmarks.

Additionally, while the use of post-pricing CEA is positioned as a mechanism for bidirectional price adjustment, price increases have not been seen in practice. Instead, CEA functions predominantly as a tool for price erosion, creating a disconnect between policy intent and real-world outcomes. As a result, the lack of credible upside further compounds launch hesitancy in Japan, even when additional value is generated post-launch.

Conclusion

Japan’s FY2026 drug pricing reform highlights a clear policy priority of cost containment. While some adjustments, such as the abolition of the spillover rule, demonstrate responsiveness to industry feedback, the broader framework intensifies pricing pressure through more aggressive blockbuster repricing, annual price revisions, and reduced attractiveness of foreign price adjustment (FPA).

The central policy dilemma of sustaining a financially stable healthcare system while maintaining strong incentives for innovation is seen as unresolved by many. Without predictable mechanisms to reward therapeutic value during patent exclusivity, concerns arise regarding long-term commercial success, especially amidst potential referencing for US MFN pricing.

As FY2026 reforms are finalized and implemented, Japan’s position as a priority launch market can be seen to be at risk and will increasingly depend on whether future adjustments are made to reward innovation, or whether cost containment will continue to dominate the policy landscape.


Article written by Jason King, Anoud Naeem and Amy Morgan, Windrose Consulting Group


Adam Foster
Next

The Emergence of Cancer Vaccines: Reframing Value Demonstration, Pricing, and Access